CL2014001559A1 - Sistema terapeutico transdermico que comprende una estructura de capa autoadhesiva que contiene buprenorfina la cual comprende a) una capa de respaldo impermeable a buprenorfina y b) una capa adhesiva sensible a la presion que contiene buprenorfina, la cual contacta la piel y que comprende al menos un adhesivo, buprenorfina y un acido carboxilico; su metodo de fabricacion, util para tratar el dolor. - Google Patents
Sistema terapeutico transdermico que comprende una estructura de capa autoadhesiva que contiene buprenorfina la cual comprende a) una capa de respaldo impermeable a buprenorfina y b) una capa adhesiva sensible a la presion que contiene buprenorfina, la cual contacta la piel y que comprende al menos un adhesivo, buprenorfina y un acido carboxilico; su metodo de fabricacion, util para tratar el dolor.Info
- Publication number
- CL2014001559A1 CL2014001559A1 CL2014001559A CL2014001559A CL2014001559A1 CL 2014001559 A1 CL2014001559 A1 CL 2014001559A1 CL 2014001559 A CL2014001559 A CL 2014001559A CL 2014001559 A CL2014001559 A CL 2014001559A CL 2014001559 A1 CL2014001559 A1 CL 2014001559A1
- Authority
- CL
- Chile
- Prior art keywords
- buprenorphine
- adhesive layer
- skin
- contacts
- self
- Prior art date
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title 4
- 229960001736 buprenorphine Drugs 0.000 title 4
- 239000010410 layer Substances 0.000 title 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 title 1
- 239000000853 adhesive Substances 0.000 title 1
- 230000001070 adhesive effect Effects 0.000 title 1
- 239000012790 adhesive layer Substances 0.000 title 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569609P | 2011-12-12 | 2011-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001559A1 true CL2014001559A1 (es) | 2014-10-03 |
Family
ID=47754872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001559A CL2014001559A1 (es) | 2011-12-12 | 2014-06-12 | Sistema terapeutico transdermico que comprende una estructura de capa autoadhesiva que contiene buprenorfina la cual comprende a) una capa de respaldo impermeable a buprenorfina y b) una capa adhesiva sensible a la presion que contiene buprenorfina, la cual contacta la piel y que comprende al menos un adhesivo, buprenorfina y un acido carboxilico; su metodo de fabricacion, util para tratar el dolor. |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20140363487A1 (enExample) |
| EP (1) | EP2790685B1 (enExample) |
| JP (2) | JP6289378B2 (enExample) |
| KR (1) | KR102014565B1 (enExample) |
| CN (2) | CN107669662A (enExample) |
| AP (1) | AP4036A (enExample) |
| AR (1) | AR089201A1 (enExample) |
| AU (1) | AU2012327247B2 (enExample) |
| BR (1) | BR112014014137A2 (enExample) |
| CA (1) | CA2858531C (enExample) |
| CL (1) | CL2014001559A1 (enExample) |
| CO (1) | CO7000779A2 (enExample) |
| CR (1) | CR20140321A (enExample) |
| DE (1) | DE112012005185T5 (enExample) |
| EA (1) | EA201491164A1 (enExample) |
| ES (1) | ES2647516T3 (enExample) |
| GB (1) | GB2512007B8 (enExample) |
| IL (1) | IL233025A0 (enExample) |
| MX (1) | MX352795B (enExample) |
| PE (1) | PE20142341A1 (enExample) |
| PH (1) | PH12014501231A1 (enExample) |
| PL (1) | PL2790685T3 (enExample) |
| SG (2) | SG10201604754VA (enExample) |
| TN (1) | TN2014000233A1 (enExample) |
| TW (1) | TW201338813A (enExample) |
| WO (1) | WO2013088254A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| DE102006054731B4 (de) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
| BRPI0811319A2 (pt) | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
| EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| CA3202964A1 (en) | 2011-12-06 | 2013-06-13 | Delta Faucet Company | Ozone distribution in a faucet |
| EP2790685B1 (en) * | 2011-12-12 | 2017-08-16 | LTS LOHMANN Therapie-Systeme AG | Transdermal delivery system comprising buprenorphine |
| US9566241B2 (en) * | 2012-02-21 | 2017-02-14 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片 |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| LT2810646T (lt) | 2013-06-04 | 2016-10-25 | Lts Lohmann Therapie-Systeme Ag | Transderminė tiekimo sistema |
| CN105358139B (zh) | 2013-07-03 | 2020-10-16 | Lts罗曼治疗方法有限公司 | 具有电子元件的经皮治疗系统 |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| ES2954087T3 (es) * | 2014-05-20 | 2023-11-20 | Lts Lohmann Therapie Systeme Ag | Sistema de administración transdérmica que incluye un mediador de interfase |
| CA2948220C (en) | 2014-05-20 | 2023-06-20 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
| CN106456567A (zh) | 2014-05-20 | 2017-02-22 | Lts勒曼治疗系统股份公司 | 在经皮递送系统中调节活性剂释放的方法 |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| SG11201707350TA (en) * | 2015-03-10 | 2017-10-30 | Rhodes Tech | Acetate salt of buprenorphine and methods for preparing buprenorphine |
| US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
| EP3067050A1 (en) | 2015-03-13 | 2016-09-14 | Acino AG | Transdermal therapeutic system with an overtape comprising two adhesive layers |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| EP3349737A4 (en) * | 2015-09-14 | 2019-05-15 | Amneal Pharmaceuticals LLC | SYSTEM FOR TRANSDERING |
| CN115093008B (zh) | 2015-12-21 | 2024-05-14 | 德尔塔阀门公司 | 包括消毒装置的流体输送系统 |
| RU2018133932A (ru) | 2016-04-01 | 2020-05-12 | Терапьютиксмд, Инк. | Фармацевтическая композиция стероидного гормона |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
| WO2019064026A1 (en) | 2017-09-29 | 2019-04-04 | Orexo Ab | NEW PHARMACEUTICAL COMPOSITIONS |
| GB201716830D0 (en) | 2017-10-13 | 2017-11-29 | Cambrex Charles City Inc | New Process |
| BR112020018607A2 (pt) | 2018-03-13 | 2020-12-29 | Lts Lohmann Therapie-Systeme Ag | Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone acrílico |
| WO2019175106A1 (en) | 2018-03-13 | 2019-09-19 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system comprising a silicone acrylic hybrid polymer |
| BR112020018300A2 (pt) | 2018-03-13 | 2020-12-22 | Lts Lohmann Therapie-Systeme Ag | Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone e acrílico |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| WO2020102695A1 (en) | 2018-11-16 | 2020-05-22 | Cti (Assignment For Benefit Of Creditors) Llc | Thermally regulated transdermal drug delivery system |
| GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
| CN113952319A (zh) * | 2021-11-30 | 2022-01-21 | 烟台大学 | 一种含丁丙诺啡的骨架型透皮贴剂及其制备方法 |
| CN114397411A (zh) * | 2021-12-14 | 2022-04-26 | 苏州高迈药业有限公司 | 一种评价利丙双卡因乳膏的方法 |
| WO2024040897A1 (zh) * | 2022-08-24 | 2024-02-29 | 新领医药技术(深圳)有限公司 | 沙利度胺或其类似物透皮贴剂及其制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US119585A (en) * | 1871-10-03 | Improvement in horse-collars and hames | ||
| GB1136214A (en) | 1965-06-15 | 1968-12-11 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
| US3474101A (en) | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
| US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
| CA2002299A1 (en) | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
| DE3939376C1 (enExample) * | 1989-11-29 | 1991-05-08 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De | |
| US5240711A (en) | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
| US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
| US5635203A (en) * | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
| DE4446600A1 (de) * | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen |
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| DE19922662C1 (de) | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
| BR0012152A (pt) | 1999-07-02 | 2002-03-12 | Lohmann Therapie Syst Lts | Sistema de microrreservatórios na base de polissiloxanos e solventes ambifìlicos |
| DE19958554C2 (de) | 1999-07-02 | 2002-06-13 | Lohmann Therapie Syst Lts | Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung |
| WO2001014336A1 (en) * | 1999-08-20 | 2001-03-01 | Nippon Kayaku Kabushiki Kaisha | Benzene derivatives substituted by aromatic ring and process for producing the same |
| ATE431145T1 (de) | 2000-02-08 | 2009-05-15 | Euro Celtique Sa | Missbrauchssichere orale opioid-agonist zubereitungen |
| JP4659943B2 (ja) * | 2000-02-25 | 2011-03-30 | 帝三製薬株式会社 | 塩酸ブプレノルフィン含有貼付剤 |
| US6844727B2 (en) * | 2000-06-28 | 2005-01-18 | Baker Hughes Incorporated | Method and apparatus of reducing ringing in a nuclear magnetic resonance probe |
| US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
| WO2002083135A2 (en) | 2001-02-16 | 2002-10-24 | Grünenthal GmbH | Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence |
| DE10141651B4 (de) | 2001-08-24 | 2007-02-15 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung |
| DE10213772A1 (de) | 2002-03-27 | 2003-10-09 | Gruenenthal Gmbh | Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen |
| US20050118245A1 (en) | 2002-03-27 | 2005-06-02 | Wilsmann Klaus M. | Assembled unit consisting of individually separable, transdermal, therapeutic systems |
| US20050191340A1 (en) * | 2002-08-09 | 2005-09-01 | Gruenenthal Gmbh | Opioid-receptor antagonists in transdermal systems having buprenorphine |
| EP1526848B1 (de) * | 2002-08-09 | 2007-07-18 | Grünenthal GmbH | Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin |
| US7270830B2 (en) | 2002-12-13 | 2007-09-18 | Purdue Pharma L.P. | Transdermal buprenorphine dosage regimen for analgesia |
| RU2324372C2 (ru) | 2003-03-25 | 2008-05-20 | Моринда, Инк. | Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека |
| US8790689B2 (en) * | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
| US7182955B2 (en) * | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
| DE102004045599A1 (de) | 2004-09-17 | 2006-03-23 | Grünenthal GmbH | System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen |
| DE102004062647A1 (de) | 2004-12-21 | 2006-06-29 | Kronotec Ag | Holzfaserdämmstoffplatte bzw.- matte |
| DE102004062614B4 (de) | 2004-12-24 | 2011-12-29 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung |
| DE102006054731B4 (de) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
| DE102006054732B4 (de) | 2006-11-21 | 2010-12-30 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren |
| EP2366388A1 (de) | 2010-03-17 | 2011-09-21 | Ratiopharm GmbH | Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin |
| EP2790685B1 (en) * | 2011-12-12 | 2017-08-16 | LTS LOHMANN Therapie-Systeme AG | Transdermal delivery system comprising buprenorphine |
| AU2013205080B2 (en) | 2012-12-12 | 2016-07-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal Delivery System |
| LT2810646T (lt) | 2013-06-04 | 2016-10-25 | Lts Lohmann Therapie-Systeme Ag | Transderminė tiekimo sistema |
-
2012
- 2012-12-12 EP EP12826670.7A patent/EP2790685B1/en active Active
- 2012-12-12 TW TW101146918A patent/TW201338813A/zh unknown
- 2012-12-12 JP JP2014546672A patent/JP6289378B2/ja active Active
- 2012-12-12 PE PE2014000948A patent/PE20142341A1/es not_active Application Discontinuation
- 2012-12-12 CN CN201711075001.2A patent/CN107669662A/zh active Pending
- 2012-12-12 GB GB1412385.5A patent/GB2512007B8/en active Active
- 2012-12-12 PL PL12826670T patent/PL2790685T3/pl unknown
- 2012-12-12 ES ES12826670.7T patent/ES2647516T3/es active Active
- 2012-12-12 SG SG10201604754VA patent/SG10201604754VA/en unknown
- 2012-12-12 BR BR112014014137A patent/BR112014014137A2/pt not_active Application Discontinuation
- 2012-12-12 AU AU2012327247A patent/AU2012327247B2/en not_active Ceased
- 2012-12-12 WO PCT/IB2012/002973 patent/WO2013088254A1/en not_active Ceased
- 2012-12-12 CN CN201280069476.XA patent/CN104114161A/zh active Pending
- 2012-12-12 SG SG11201403162XA patent/SG11201403162XA/en unknown
- 2012-12-12 DE DE112012005185.8T patent/DE112012005185T5/de not_active Ceased
- 2012-12-12 AR ARP120104673A patent/AR089201A1/es unknown
- 2012-12-12 EA EA201491164A patent/EA201491164A1/ru unknown
- 2012-12-12 KR KR1020147019186A patent/KR102014565B1/ko active Active
- 2012-12-12 MX MX2014007020A patent/MX352795B/es active IP Right Grant
- 2012-12-12 US US14/364,192 patent/US20140363487A1/en not_active Abandoned
- 2012-12-12 CA CA2858531A patent/CA2858531C/en active Active
- 2012-12-12 AP AP2014007779A patent/AP4036A/en active
-
2014
- 2014-05-28 TN TNP2014000233A patent/TN2014000233A1/en unknown
- 2014-05-30 PH PH12014501231A patent/PH12014501231A1/en unknown
- 2014-06-08 IL IL233025A patent/IL233025A0/en unknown
- 2014-06-12 CL CL2014001559A patent/CL2014001559A1/es unknown
- 2014-07-04 CR CR20140321A patent/CR20140321A/es unknown
- 2014-07-11 CO CO14149730A patent/CO7000779A2/es unknown
-
2016
- 2016-01-11 US US14/992,122 patent/US9549903B2/en active Active
- 2016-10-07 JP JP2016198650A patent/JP2017036304A/ja active Pending
- 2016-10-10 US US15/289,507 patent/US20170049713A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,920 patent/US20200306204A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014001559A1 (es) | Sistema terapeutico transdermico que comprende una estructura de capa autoadhesiva que contiene buprenorfina la cual comprende a) una capa de respaldo impermeable a buprenorfina y b) una capa adhesiva sensible a la presion que contiene buprenorfina, la cual contacta la piel y que comprende al menos un adhesivo, buprenorfina y un acido carboxilico; su metodo de fabricacion, util para tratar el dolor. | |
| CL2015001577A1 (es) | Uso de un sistema de liberación transdermico de buprenorfina: a) capa de respaldo impermeable a buprenorfina; b) capa matricial conteniendo buprenorfina que a su vez comprende: i) base polimerica; ii) buprenorfina y iii) acido carboxilico; y c) capa de contacto con la piel; sistema terapeutico transdermico; metodo de preparacion | |
| NI201500170A (es) | Sistema de liberación transdermico | |
| SG11201503780TA (en) | Water-dispersed pressure-sensitive adhesive composition, pressure-sensitive adhesive layer, pressure-sensitive adhesive sheet, and laminate comprising pressure-sensitive adhesive layer or pressure-sensitive adhesive sheet | |
| CL2013001393A1 (es) | Estructura para la extraccion de agua a partir del aire, que comprende una parte absorbente y una parte desorbente donde dicha parte absorbente comprende una superficie que tiene una capa de un liquido higroscopico, y donde dicha parte desorbente comprende una estructura tipo sandwich para separar el agua del liquido higroscopico, comprendiendo dicha estructura tipo sandwich una lamina o capa calentada, un espacio, una capa de material y una lamina o capa enfriada; uso de una estructura; metodo de cultivo | |
| BRPI0906107A2 (pt) | sistema, aparelho e método para aplicar uma pressão reduzida a um local de tecido em um pé, e, método de fabricação de um aparelho para aplicação de pressão reduzida a um local de tecido em um pé. | |
| BR112013012492A2 (pt) | sistema de apoio antiextrusão, sistema de elemento de engaxetamento tendo sistema de apoio, e método | |
| CL2015003185A1 (es) | Aparato para la electroobtención o electrorefinación | |
| BR112015003068A2 (pt) | montagem de pastilha de freio a disco e sistema de retenção e método. | |
| BRPI1013138A2 (pt) | método, dispositivo e sistema para controlar a alocação de indenticador de túnel | |
| BRPI0913554A2 (pt) | curativo para aplicação de pressão reduzida em um local de tecido, sistema para aplicar uma pressão reduzida em um local de tecido, método para aplicar pressão reduzida em um local de tecido, método de fabricação de um curativo para aplicar uma pressão reduzida em um local de tecido e curativo de ferida de pressão reduzida | |
| PL2536605T3 (pl) | Wzmacniacz siły hamowania jak również sposób i urządzenie do jego pracy | |
| WO2012124966A3 (ko) | 펜타닐 경피 패치제 | |
| BR112013010078A2 (pt) | sistema de prevenção de ferida de pressão e método para evitar o desenvolvimento de feridas de pressão de um indivíduo | |
| BR112012029233A2 (pt) | sistema de frenagem para cama hospitalar | |
| BRPI0918976A2 (pt) | matriz, sistema e método para coextrusar uma pluralidade de camadas fluidas | |
| BR112014015294A8 (pt) | método cosmétido; de referência de cor, especialmente para implementar método; sistema para implementar o metodo, pacote de software de computador para implementar o método | |
| BR112013014616A2 (pt) | sistema terapêutico transdérmico para a administração de uma substância ativa | |
| BR112012014075A2 (pt) | aparelho, sistema e método para empregar um ups. | |
| BRPI0909653A2 (pt) | sistema terapêutico transdérmico com membrama estabilizada | |
| BR112015003064A2 (pt) | montagem de pastilha de freio a disco e sistema de retenção e método | |
| UA114101C2 (xx) | Трансдермальна терапевтична система для введення фентанілу або його аналога | |
| CL2015000857A1 (es) | Una composicion farmaceutica que consiste en una primera capa que comprende metformina y una segunda capa que comprende gemigliptina; su metodo de preparacion, util para la prevencion y el tratamiento de la diabetes. | |
| CL2013003585A1 (es) | Procedimiento para preparar una tableta de caldo que tiene dos o más capas, el cual consiste en las etapas de (a) formar una primera capa de la tableta, (b) formar una segunda capa de la tableta y (c) comprimir las dos capas para formar la tableta. | |
| WO2014053708A3 (en) | A part of a package |